Procollagen type 1 N-terminal propeptide (P1NP) and Carboxy-terminal cross-linked telopeptide type 1 collagen (CTX) in patients who underwent Bariatric surgery Roux-en-Y gastric bypass (RYGB) Sleeve gastrectomy (SG) Sleeve gastrectomy with duodenojejunal bypass (SGDJB) Bariatric surgery Gastric Bypass Gastrectomy procollagen Type I N-terminal peptide collagen type I trimeric cross-linked peptide
Conditions
Interventions
Patient who underwent sleeve gastrectomy,Patient who underwent sleeve gastrectomy with duodenojejunal bypass,Patient who underwent Roux-en-Y gastric bypass
Screening,Screening,Screening
SG,SGDJB,RYGB
Sponsors
Thai Red Cross Society
Ratchadapisek Research Funds
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients with morbid obesity (BMI >= 40 or BMI >= 35 with obesity-related comorbidities) who are undergoing bariatric surgery at KCMH 2. Age between 18 and 70 years 3. Patients with morbid obesity undergoing bariatric surgery from January 2023 to January 2026 at KCMH who have previously given consent to participate in the research project IRB No. 612/57 named Hormonal changes and remission of type 2 diabetes in Thai obese subjects after bariatric surgery and whose plasma samples (Pre-op and at 6 months post-op) are available for analysis.
Exclusion criteria
Exclusion criteria: 1. Patients with severe illnesses, including active cancer undergoing treatment or any condition requiring hospitalization before or within 6 months after bariatric surgery 2. Patients with severe psychiatric disorders, such as depression, eating disorders (e.g., binge eating disorder), or psychosis 3. Pregnant or breastfeeding women within 6 months after bariatric surgery 4. Individuals who refuse to consent to participate in the research or cannot be followed up after surgery. 5. Patients who have previously undergone bariatric surgery by other methods, such as having undergone sleeve gastrectomy and now undergoing Roux-en-Y gastric bypass
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Procollagen type 1 N-terminal propeptide (P1NP) baseline and post-operative 6 months Electrochemiluminescence Immunoassay (ECLIA) method (Roche) | — |
Secondary
| Measure | Time frame |
|---|---|
| Carboxy-terminal cross-linked telopeptide type 1 collagen (CTX) baseline and post-operative 6 months Electrochemiluminescence Immunoassay (ECLIA) method (Roche) | — |
Countries
Thailand
Contacts
Public ContactJantita Buranakulkijkarn
Division of Endocrinology and Metabolism, Department of Medicine
Outcome results
None listed